Real-world Studies of CDK4/6 Inhibitors

Summary

A single-center, real-world study evaluated the clinical outcomes and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- advanced breast cancer, and conducted a summary analysis of the clinical treatment options after the progression of CDK4/6 inhibitors.

Eligibility

Inclusion Criteria:

1. Age ≥ 18 years old;
2. Patients diagnosed with HR+/HER2- (as defined by the ASCO/CAP guidelines) advanced breast cancer who were treated in our hospital from March 2022 to March 2025;
3. Received CDK4/6 inhibitors (including but not limited to the four currently marketed ones: palbociclib, abemaciclib, ribociclib, and dalpiciclib) as advanced-stage treatment for at least one cycle;
4. Have complete medical history records, including demographic information, pathological reports, treatment records, laboratory test results, and imaging examination reports, etc.

Exclusion Criteria:

1. Incomplete medical history data.
2. Only received CDK4/6 inhibitors monotherapy.
3. Received CDK4/6 inhibitors as neoadjuvant/postoperative adjuvant intensification therapy.

Conditions2

Browse More Trials